Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24749936 | 0.82 | NFE2L2 (0.39) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21667992 | 0.80 | NFE2L2 (0.38) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3324909 | 0.80 | GRIN2D (0.48) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3324915 | 0.80 | GRIN2D (0.48) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31182406 | 0.76 | GRIN2D (0.59) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2161993 | 0.76 | GRIN2D (0.59) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3654924 | 0.76 | GRIN2D (0.59) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1710498 | 0.76 | GRIN2D (0.59) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1710501 | 0.76 | GRIN2D (0.59) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27372237 | 0.76 | NFE2L2 (0.54) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-8093274-B2 | Inhibitors of protein prenyltransferases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100063114-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063114-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | GGT1, FNTA, FNTB | NFE2L2 3552/4885GRIN2D 4855/4885GRIN3B 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.